Skip to content
The Nexus
DossierENTITY

BIIB080

Coverage of BIIB080 in the Nexus archive.

Earliest in view: May 14 · 11:08 UTCMost recent: May 14 · 11:08 UTC
Co-mentioned in this coverage
Biogenorganization1Alzheimer's diseasetopic1diranersentopic1
Recent coverage
  • HEALTHMay 14 · 11:08 UTCSTAT NEWS
    STAT+: Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage study

    Biogen's tau-targeting Alzheimer's drug diranersen showed mixed results in a mid-stage clinical trial, reducing tau levels and slowing cognitive decline, but failed to achieve its primary efficacy goal. The study investigated three escalating dosing regimens, with the lowest dose showing the best results. Biogen reported that tau reductions correlated to a slowing of cognitive decline.